Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Ping Chen, Ph.D., William Blum, M.D., Josephine Aimiuwu, B.S., Vijayasarathi Upadhyayula, Ph.D., Zhongfa Liu, Ph.D., Shujun Liu, Ph.D., Jiuxia Pang, B.S., Alison Walker, M.D., Rebecca B. Klisovic, M.D., Ramiro Garzon, M.D., Michael R. Grever, M.D., Miguel Villalona-Calero, M.D., John C. Byrd, M.D., Kenneth K Chan, Ph.D., Guido Marcucci, M.D.

Blood (2009) 114 (22): 3782.

https://doi.org/10.1182/blood.V114.22.3782.3782

Published: 2009

Journal Articles

TLR7/8 Differentially Regulates Fcγ Receptor Expression and Function.

Jonathan P Butchar, Ph.D., Payal Mehta, M.S., Steven E Justiniano, Ph.D., Kristan D Guenterberg, M.D., Thirumala-Devi Kanneganti, Ph.D., Amal Amer, M.D., Ph.D., Natarajan Muthusamy, Ph.D., David Jarjoura, Ph.D., Clay B Marsh, M.D., William E Carson, III, M.D., John C Byrd, M.D., Susheela Tridandapani, Ph.D.

Blood (2009) 114 (22): 3594.

https://doi.org/10.1182/blood.V114.22.3594.3594

Published: 2009

Journal Articles

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.

Ian W Flinn, M.D., Ph.D., John C. Byrd, M.D., Richard R Furman, MD, Jennifer R Brown, MD, PhD, Don M Benson, MD, PhD, Steven E Coutre, MD, Brad S Kahl, M.D., B. Douglas Smith, M.D., Nina D. Wagner-Johnston, MD, Stephen E Spurgeon, MD, Neill A. Giese, Ph.D., Albert S Yu, MD

Blood (2009) 114 (22): 922.

https://doi.org/10.1182/blood.V114.22.922.922

Published: 2009

Journal Articles

del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.

Leslie A. Andritsos, MD, Jeffrey Jones, M.D., Gerard Lozanski, M.D., Thomas S. Lin, M.D., Kristie A. Blum, M.D., Michael R. Grever, M.D., David Jarjoura, Ph.D., John C. Byrd, M.D., Nyla Heerema, M.D.

Blood (2007) 110 (11): 2073.

https://doi.org/10.1182/blood.V110.11.2073.2073

Published: 2007

Journal Articles

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Leslie A. Andritsos, MD, Beth Fischer, R.N., Thomas S. Lin, M.D., Kristie A. Blum, M.D., Jeffrey A. Jones, M.D., Mollie E. Moran, C.N.P., John C. Byrd, M.D., Michael R. Grever, M.D.

Blood (2007) 110 (11): 3128.

https://doi.org/10.1182/blood.V110.11.3128.3128

Published: 2007

Journal Articles

Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.

Leslie A. Andritsos, MD, Amy J. Johnson, Ph.D., William Blum, M.D., Cheryl Kefauver, R.N., Farrukh Awan, M.D., Lisa L. Smith, Rosa Lapalombella, Da-Sheng Wang, Robert D. Knight, Ching-Shih Chen, Ph.D., John C. Byrd, M.D.

Blood (2007) 110 (11): 4727.

https://doi.org/10.1182/blood.V110.11.4727.4727

Published: 2007

Journal Articles

Protein Tyrosine Phosphatase Receptor Type O (PTPRO) Exhibits Tumor Suppressor Properties in K562 Cells by Dephosphorylating Bcr-Abl.

Sarmila Majumder, PhD, Tasneem Motiwala, Ph.D, Kalpana Ghoshal, Ph.D, Huban Kutay, Ph.D, Jharna Datta, Ph.D, David Lucas, Ph.D, John C. Byrd, M.D., Samson T. Jacob, Ph.D

Blood (2007) 110 (11): 2914.

https://doi.org/10.1182/blood.V110.11.2914.2914

Published: 2007

Journal Articles

FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph 1 ALL Patients.

Ramasamy Santhanam, PhD, Paolo Neviani, D.Sci, Anna Eiring, B.S., Joshua Oaks, B.S., Mario Notari, D.Sci, Bradley W. Blaser, Ph.D., Shujun Liu, Ph.D, Rossana Trotta, Ph.D, Natarajan Muthusamy, Ph.D, Guido Marcucci, M.D., Carlo Gambacorti, M.D., Denis-Claude Roy, M.D., Michael A. Caligiuri, M.D., Clara D. Bloomfield, M.D., Ching-Shih Chen, Ph.D, John C. Byrd, M.D., Danilo Perrotti, MD, PhD

Blood (2006) 108 (11): 288.

https://doi.org/10.1182/blood.V108.11.288.288

Published: 2006

Journal Articles

NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL.

Xiaobin B. Zhao, MS, Joshi Trupti, B.S., Rosa Lapalombella, Ph. D., Carolyn Cheney, B.S., Aruna Gowda, M.D., Martha S. Hayden-Ledbetter, Ph. D., Peter R. Baum, Ph.D., Thomas S. Lin, M.D., Ph.D., David Jarjoura, Ph.D., Amy Lehman, M.S., Robert J. Lee, Ph.D., Michael A. Caligiuri, M.D., Susheela Tridandapani, Ph.D., Natarajan Muthusamy, Ph.D., John C. Byrd, M.D.

Blood (2006) 108 (11): 135.

https://doi.org/10.1182/blood.V108.11.135.135

Published: 2006

Journal Articles

Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.

Emanuela M. Ghia, PhD, Laura Z. Rassenti, Ph.D., George F. Widhopf, Ph.D., Donna S. Neuberg, Ph.D., Michael J. Keating, M.D., William G. Wierda, M.D., Ph.D., John G. Gribben, M.D., Jennifer R. Brown, M.D., Ph.D., Ian W. Flinn, M.D., Ph.D., Kanti R. Rai, M.D., John C. Byrd, M.D., Neil E. Kay, M.D., Andrew W. Greaves, B.S., Thomas J. Kipps, M.D.,Ph.D.

Blood (2006) 108 (11): 2774.

https://doi.org/10.1182/blood.V108.11.2774.2774

Published: 2006

Journal Articles

FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.

Qing Liu, MS, Xiaobin Zhao, M.S., Frank Frissora, M.S., Yihui Ma, M.S., Ramasamy Santhanam, Ph.D., Danilo Perrotti, M.D.,Ph.D., Ching-Shih Chen, Ph.D., James T. Dalton, Ph.D., John C. Byrd, M.D., Natarajan Muthusamy, DVM.,Ph.D.

Blood (2006) 108 (11): 2095.

https://doi.org/10.1182/blood.V108.11.2095.2095

Published: 2006

Journal Articles

Humanized Anti CD-40 Antibody SGN-40 Effectively Induces Cytotoxicity Against Chronic Lymphocytic Leukemia (CLL) Cells through Antibody Mediated Cytotoxicity and Demonstrates Modest Biologic Evidence of CD40 Activation.

Aruna C. Gowda, MD, Xiaobin B. Zhao, M.S, Carolyn Cheney, BS, Najma Mehter, BS, Gerard Lozanski, M.D, Thomas S. Lin, M.D PhD, Sara Guster, M.S, J. G. Drachman, M.D, Natarajan Muthusamy, DvM, PhD, John C. Byrd, M.D

Blood (2005) 106 (11): 2966.

https://doi.org/10.1182/blood.V106.11.2966.2966

Published: 2005

Journal Articles

Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia.

James Woodworth, Ph.D., Bryan R. Leigh, M.D., Susan O’Brien, M.D., Ian Flinn, M.D., Thomas J. Kipps, M.D., Mark A. Weiss, M.D., Kanti Rai, M.D., Aron Thall, Ph.D., Dee Wynne, R.N., John C. Byrd, M.D.

Blood (2004) 104 (11): 4831.

https://doi.org/10.1182/blood.V104.11.4831.4831

Published: 2004

Journal Articles

Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia.

John C. Byrd, M.D., Susan O’Brien, M.D., Ian Flinn, M.D., Thomas J. Kipps, M.D., Mark A. Weiss, M.D., Kanti Rai, M.D., Thomas S. Lin, M.D., Jennifer Reid, M.S., Dee Wynne, R.N., Bryan R. Leigh, M.D.

Blood (2004) 104 (11): 2503.

https://doi.org/10.1182/blood.V104.11.2503.2503

Published: 2004

Journal Articles

Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report.

William Blum, M.D., Kristie A. Blum, M.D., Cheryl Kefauver, R.N., Mollie Moran, C.R.N.P., Kenneth Chan, Ph.D., John C. Byrd, M.D., Spero Cataland, M.D., Michael R. Grever, M.D., Guido Marcucci, M.D.

Blood (2004) 104 (11): 4528.

https://doi.org/10.1182/blood.V104.11.4528.4528

Published: 2004

Journal Articles

Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens.

William Blum, M.D., Sam Penza, M.D., Sherif Farag, M.D., Belinda Avalos, M.D., Guido Marcucci, M.D., Thomas Lin, M.D., John C. Byrd, M.D., Patrick Elder, Edward A. Copelan, M.D.

Blood (2004) 104 (11): 5123.

https://doi.org/10.1182/blood.V104.11.5123.5123

Published: 2004

NARROW

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

TLR7/8 Differentially Regulates Fcγ Receptor Expression and Function.

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.

del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.

Protein Tyrosine Phosphatase Receptor Type O (PTPRO) Exhibits Tumor Suppressor Properties in K562 Cells by Dephosphorylating Bcr-Abl.

FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph 1 ALL Patients.

NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL.

Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.

FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.

Humanized Anti CD-40 Antibody SGN-40 Effectively Induces Cytotoxicity Against Chronic Lymphocytic Leukemia (CLL) Cells through Antibody Mediated Cytotoxicity and Demonstrates Modest Biologic Evidence of CD40 Activation.

Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia.

Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia.

Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report.

Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only